These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 31556337)
1. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission. Andrews C; Lipton J Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337 [No Abstract] [Full Text] [Related]
2. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170 [TBL] [Abstract][Full Text] [Related]
4. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. Nickel RS; Daves M; Keller F Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962 [No Abstract] [Full Text] [Related]
5. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia. Engel NW; Constantin A; Fowlkes S; Assouline S J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687 [No Abstract] [Full Text] [Related]
6. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Sanford D; Kantarjian H; Skinner J; Jabbour E; Cortes J Haematologica; 2015 Dec; 100(12):e494-5. PubMed ID: 26341741 [No Abstract] [Full Text] [Related]
7. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. Breccia M; Abruzzese E; Iurlo A; Gozzini A; Isidori A; Gangemi D; Pregno P; Alimena G Haematologica; 2016 Jun; 101(6):e267-8. PubMed ID: 27252515 [No Abstract] [Full Text] [Related]
8. Success is built on failures: tackling the challenge of ponatinib failure. Hiwase D; Ross D Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246 [No Abstract] [Full Text] [Related]
9. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib. Mayer K; Gielen GH; Willinek W; Müller MC; Wolf D Leukemia; 2014 Apr; 28(4):976-7. PubMed ID: 24170029 [No Abstract] [Full Text] [Related]
10. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia. Shah NP Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660 [No Abstract] [Full Text] [Related]
11. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation. Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382 [No Abstract] [Full Text] [Related]
12. Should vascular effects of newer treatments be addressed more completely? Yang EH; Watson KE; Herrmann J Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824 [No Abstract] [Full Text] [Related]
13. Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. Iurlo A; Cattaneo D; Malato A; Accurso V; Annunziata M; Gozzini A; Scortechini AR; Bucelli C; Scalzulli E; Attolico I; Maggi A; Martino B; Caocci G; Abruzzese E; Pregno P; Luciano L; Breccia M Am J Hematol; 2020 Oct; 95(10):E260-E263. PubMed ID: 32557788 [No Abstract] [Full Text] [Related]
14. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry. Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128 [TBL] [Abstract][Full Text] [Related]
15. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia]. Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110 [No Abstract] [Full Text] [Related]